Ulka Vaishampayan Profile
Ulka Vaishampayan

@DrVaishampayan

Followers
1K
Following
597
Media
15
Statuses
715

I'm trendy fun loving but serious and hard working.

Ann arbor MI
Joined June 2009
Don't wanna be here? Send us removal request.
@DrVaishampayan
Ulka Vaishampayan
4 years
@tompowles1 Support SWOG 1931 PROBE trial. Delayed nephrectomy has a potential role to improve outcomes in management of synchronous met RCC
2
3
10
@DrVaishampayan
Ulka Vaishampayan
3 years
Comprehensive overview and remarkable presented
@montypal
Sumanta K. Pal, MD, FASCO
3 years
In the final session of @ASCO #GU23, @markballmd @NIH cites the diverse outcomes across series with surgery for #kidneycancer following IO. Terrific, comprehensive overview. Ultimately an answer will hopefully come from @SWOG #PROBE, led by @DrVaishampayan & @HyungLKim!
1
0
5
@montypal
Sumanta K. Pal, MD, FASCO
3 years
Lots of folks up bright & early to discuss @theNCI trials from @SWOG, @eaonc, @NRGonc & @ALLIANCE_org ahead of sessions at @ASCO #GU23! @TiansterZhang @utswcancer kicks off the mtg w discussion of #PDIGREE, brilliant study led by her & @DrChoueiri @DanaFarber. Next up: #PROBE!
1
8
47
@DrVaishampayan
Ulka Vaishampayan
3 years
Let’s come together to tackle the RCC problem
0
0
5
@DrVaishampayan
Ulka Vaishampayan
3 years
Exciting molecular data from CTC profiling collaboration between Datar Genetics and ⁦@UMRogelCancer
0
0
4
@DrVaishampayan
Ulka Vaishampayan
3 years
Getting the patient perspectives on survivorship in met RCC. Kudos for getting the patient voice heard. ⁦@ASCO⁩ ⁦@kcCURE
0
6
15
@DrVaishampayan
Ulka Vaishampayan
3 years
@DrVaishampayan
Ulka Vaishampayan
3 years
touting S1931 PROBE trial in met RCC. Hope u can join and support this unique study exploring role of cytoreductive nephrectomy in the setting of immune therapy. @Huntsman_GU @ASCO @wandering_gu @PGrivasMDPhD @montypal
0
0
1
@DrVaishampayan
Ulka Vaishampayan
3 years
@SWOG
SWOG Cancer Research Network
3 years
#NCTN #clincialtrials in renal cell carcinoma investigator meeting at #GU23: Feb. 18, 9 am ET/6 am PT Twin Peaks Room, or join via Zoom from https://t.co/XWdGjxrHnE. Trials include PAPMET2 (S2200) and PROBE (S1931).
0
0
2
@SWOG
SWOG Cancer Research Network
3 years
#NCTN #clincialtrials in renal cell carcinoma investigator meeting at #GU23: Feb. 18, 9 am ET/6 am PT Twin Peaks Room, or join via Zoom from https://t.co/XWdGjxrHnE. Trials include PAPMET2 (S2200) and PROBE (S1931).
1
5
8
@DrVaishampayan
Ulka Vaishampayan
3 years
touting S1931 PROBE trial in met RCC. Hope u can join and support this unique study exploring role of cytoreductive nephrectomy in the setting of immune therapy. @Huntsman_GU @ASCO @wandering_gu @PGrivasMDPhD @montypal
0
5
12
@DrVaishampayan
Ulka Vaishampayan
3 years
Please attend tomorrow sat at 6 am pacific time
@ALLIANCE_org
Alliance for Clinical Trials in Oncology
3 years
This Saturday, 2/18, 6 am PST - NCTN Trials in Renal Cell Carcinoma Investigator Meeting! Learn more about #PDIGREE #PROBE #RADICAL #SAMURAI #PAPMET2 trials! #ASCO @ALLIANCE_org @SWOG @NRGOncology @eaonc .@DrRanaMcKay .@DrVaishampayan .@maughanonc .@whallradonc .@TiansterZhang
0
0
1
@DrVaishampayan
Ulka Vaishampayan
3 years
Exciting results!
@neerajaiims
Neeraj Agarwal, MD, FASCO
3 years
Abs#603 @ASCO #GU23 by @BurottoMauricio 👉 https://t.co/dpsfGxPjek Checkmate-9ER ph3 mRCC #kidneycancer update 👉 Nivo+Cabozantinib vs Sunitinib: median OS is 49.5 vs 29.2 mos in int/poor risk pts, ORR👇 @DrChoueiri @tompowles1 @OncoAlert @urotoday @Uromigos @KidneyCancer
0
0
3
@DrVaishampayan
Ulka Vaishampayan
3 years
Looking forward to MSHO first Precision medicine symposium
0
0
4
@DrVaishampayan
Ulka Vaishampayan
3 years
Please join us and review all co op group RCC trials. We r in this together fighting RCC. @UMRogelCancer @SWOG @SupportingSWOG @kcCURE @IKCCorg
@montypal
Sumanta K. Pal, MD, FASCO
3 years
Terrific opportunity to showcase the strenghths of the cooperative group! Please attend if you are heading to @ASCO GU!
0
2
9
@montypal
Sumanta K. Pal, MD, FASCO
3 years
Terrific opportunity to showcase the strenghths of the cooperative group! Please attend if you are heading to @ASCO GU!
@TiansterZhang
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
3 years
Calling all #NCTN #kidneycancer trial PIs! Come join us at #NCTN investigator meeting discussing #PDIGREE #PROBE #RADICAL #SAMURAI #PAPMET2 trials! ✅ Sat 2/18 6am @ICSF twin peaks @ALLIANCE_org @SWOG @NRGonc @eaonc @DrRanaMcKay @DrVaishampayan @maughanonc @whallradonc #GU23
0
5
19
@DrVaishampayan
Ulka Vaishampayan
3 years
Impressive work@vitalyMargulis
@TiansterZhang
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
3 years
Packed room to hear #VitalyMargulis talk about “real cancer” — #kidneycancer with IVC thrombus. Important patient selection, careful attention & collaboration w CT surgeons, & perioperative systemic treatments — he leads a trial now open @utswcancer @UTSWUrology for IVC thrombus!
0
1
4
@DrVaishampayan
Ulka Vaishampayan
3 years
U remain inspiring and amazing
@LauraEsfeller
Laura Esfeller
3 years
Pleased to share my scans came back with good news. May makes 7 years since my #stage4 #kidneycancer diagnosis. I’ll be spending my cancerversary at SWOG’s spring meeting. The irony isn’t lost on me & feels very fitting. I never take good scans for granted. I know how lucky I am.
1
0
5
@DrVaishampayan
Ulka Vaishampayan
3 years
A way to the future!@Dr_R_Kurzrock
@Dr_R_Kurzrock
Razelle Kurzrock, MD
3 years
Precision Medicine World Congress I am walking the hallways through the precision medicine world congress and I feel like I traveled from another galaxy and found my home planet. Everywhere are the words precision medicine, personalized medicine, patient care, multi-omics
0
0
2
@DrVaishampayan
Ulka Vaishampayan
3 years
Amazing translational study design.
@NimaSharifiMD
Nima Sharifi
3 years
7/9 Eligibility includes men w/CRPC w/at least 1 copy of the adrenal-permissive HSD3B1 allele (more active biosynthesis > more likely to benefit). Men get the BMX inhibitor abivertinib + abiraterone. Will have abi-naïve & –progressing cohorts. 9 sites will participate! @ThePCCTC
1
0
0
@DrVaishampayan
Ulka Vaishampayan
3 years
Patient communication is critical and we share a video to help consider this critical study in metastatic kidney cancer. @UMRogelCancer @TiansterZhang @neerajaiims @HyungLKim @montypal @ShuchiGulati @KidneyCancerDoc @kcCURE @DrRanaMcKay @DrChoueiri @alantanmd
@SWOG
SWOG Cancer Research Network
3 years
A new video has been posted introducing patients to the @SWOG S1931 trial in #kidneycancer: Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer @DrVaishampayan https://t.co/C2pbs2epbs
0
10
22
@SWOG
SWOG Cancer Research Network
3 years
A new video has been posted introducing patients to the @SWOG S1931 trial in #kidneycancer: Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer @DrVaishampayan https://t.co/C2pbs2epbs
0
5
7